Dr Karin Oien

  • Reader (Experimental Therapeutics)

telephone: 01413549436
email: Karin.Oien@glasgow.ac.uk

Research interests

Systems Pathology of Cancer

 

Dr Oien’s pathology practice is in gastro-intestinal and liver disease, especially cancer. This is mirrored in her clinical research. Her translational and basic science has two main themes: the application of global profiling technologies to tissues for improved cancer classification, diagnosis, prediction of prognosis or treatment guidance; and the characterisation of biomarkers identified through candidate gene approaches. The aims are to identify and develop clinically useful cancer biomarkers, and to elucidate underlying biology. Current projects include: clinical trials of our algorithm for the prediction of primary site in metastatic adenocarcinoma of unknown origin; and the identification of novel biomarkers linked with outcome in pancreatic cancer.


Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Scottish Genomics Project Part time Research Doctor
    NHS Greater Glasgow and Clyde Endowment Funds
    2018 - 2019
     
  • NASH
    Innovate UK
    2018 - 2020
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • Glasgow ECMC, Stratified Medicine Programme Two
    Cancer Research UK
    2016 - 2018
     
  • Glasgow Molecular Pathology (GMP) Node
    Medical Research Council
    2015 - 2019
     
  • Glasgow Molecular Pathology Node
    Leica Biosystems Nussloch GmbH
    2015 - 2019
     
  • Stratified Medicine Clinical Hub
    Cancer Research UK
    2013 - 2013
     
  • Molecular classification of carcinomas of unknown primary (CUP): Diagnostic validation and correlation with clinical outcomes...
    Cancer Research UK
    2011 - 2015
     
  • Stratified Medicine Phase One: Clinical Hubs - March 2011
    Cancer Research UK
    2011 - 2015
     
  • Investigating personalised therapy in mouse models of pancreatic cancer.
    Medical Research Council
    2010 - 2013
     
  • The CUP-ONE trial - a multi-centre randomised phase II study comparing epirubcin, cisplatin and capecitabine with and without Erlotinib in c
    Cancer Research UK
    2009 - 2014
     
  • Contribution towards purchase of slide scanner and image analysis system for tissue microarray research
    Pathological Society of Great Britain and Ireland
    2008 - 2008
     
  • Gene expression and genetic profiling of pancreatic cancer for improved diagnosis, prediction of outcome and patient care
    Scottish Executive Health Department
    2007 - 2009
     
  • Functional characterisation of foveolin, a new gastric-specific gene, and investigation of its role in gastric carcinogenesis
    Cancer Research UK
    2002 - 2007
     

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1995
Number of items: 86.

2018

Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi:10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)

Williams, B. J., Lee, J., Oien, K. A. and Treanor, D. (2018) Digital pathology access and usage in the UK: results from a national survey on behalf of the National Cancer Research Institute's CM-Path initiative. Journal of Clinical Pathology, 71(5), pp. 463-466. (doi:10.1136/jclinpath-2017-204808) (PMID:29317516) (PMCID:PMC5916098)

Moore, D. A., Young, C. A., Morris, H. T., Oien, K. A., Lee, J. L., Jones, J. L. and Salto-Tellez, M. (2018) Time for change: a new training programme for morpho-molecular pathologists? Journal of Clinical Pathology, 71(4), pp. 285-290. (doi:10.1136/jclinpath-2017-204821) (PMID:29113995) (PMCID:PMC5868526)

Ali, A., Ali, Z., Yousafzai, Y. M. and Oien, K. A. (2018) Cancer biomarker development from basic science to clinical practice. Journal of Postgraduate Medical Institute, 32(1), pp. 3-8.

2017

Jones, J. L., Oien, K. A., Lee, J. L. and Salto-Tellez, M. (2017) Morphomolecular pathology: setting the framework for a new generation of pathologists. British Journal of Cancer, 117(11), pp. 1581-1582. (doi:10.1038/bjc.2017.340) (PMID:29123262) (PMCID:PMC5729440)

Wong, N. A.C.S., Adamczyk, L. A., Evans, S., Cullen, J., Oniscu, A. and Oien, K. A. (2017) A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma. Histopathology, 71(1), pp. 34-41. (doi:10.1111/his.13194) (PMID:28226180)

Jones, W., Allardice, G., Scott, I., Oien, K., Brewster, D. and Morrison, D. S. (2017) Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer, 17, 85. (doi:10.1186/s12885-017-3083-1) (PMID:28143449) (PMCID:PMC5282907)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi:10.1053/j.gastro.2016.09.060) (PMID:27856273)

2016

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi:10.1097/PAI.0000000000000357) (PMID:27093449)

2015

Fizazi, K., Greco, F. A., Pavlidis, N., Daugaard, G., Oien, K. and Pentheroudakis, G. (2015) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26(Sup 5), v133-v138. (doi:10.1093/annonc/mdv305) (PMID:26314775)

McGlynn, L. M., McCluney, S., Jamieson, N. B., Thomson, J., MacDonald, A. I., Oien, K., Dickson, E. J., Carter, C. R., McKay, C. J. and Shiels, P. G. (2015) SIRT3 & SIRT7: potential novel biomarkers for determining outcome in pancreatic cancer patients. PLoS ONE, 10(6), e0131344. (doi:10.1371/journal.pone.0131344) (PMID:26121130) (PMCID:PMC4487247)

Venkatpurwar, V.P., Rhodes, S. , Oien, K.A., Elliott, M.A., Tekwe, C.D., Jorgensen, H.G. and Ravi Kumar, M.N.V. (2015) Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: size does not matter. Toxicology, 330, pp. 9-18. (doi:10.1016/j.tox.2015.01.017) (PMID:25637670)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Moyes, L. H., Oien, K. A., Foulis, A. K., Fullarton, G. M. and Going, J. J. (2015) Prevalent low-grade dysplasia: the strongest predictor of malignant progression in Barrett's columnar-lined oesophagus. Gut, 65(2), pp. 360-361. (doi:10.1136/gutjnl-2015-309978) (PMID:26085438) (PMCID:PMC4752652)

2014

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Mabvuure, N. T., Maclean, L., Oien, K. and Gaya, D. (2014) Cytomegalovirus pouchitis in a patient with Crohn's disease. BMJ Case Reports, 2014(jul17), bcr2014205374-bcr2014205374. (doi:10.1136/bcr-2014-205374) (PMID:25035450)

Brewster, D. H., Lang, J., Bhatti, L. A., Thomson, C. S. and Oien, K. A. (2014) Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010. Cancer Epidemiology, 38(3), pp. 227-234. (doi:10.1016/j.canep.2014.03.010) (PMID:24726751)

Ali, A. et al. (2014) Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 14, p. 35. (doi:10.1186/1472-6890-14-35)

2013

Denley, S.M., Jamieson, N.B., McCall, P., Oien, K.C.S., Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi:10.1007/s11605-013-2168-7)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868) (PMID:23439753)

Radulescu, S. et al. (2013) Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene, 32(16), pp. 2048-2057. (doi:10.1038/onc.2012.224)

2012

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi:10.1083/jcb.201203025)

Jamieson, N.B., Mohamed, M., Oien, K.A., Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, C.R., McKay, C.J. and McMillan, D.C. (2012) The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 19(11), pp. 3581-3590. (doi:10.1245/s10434-012-2370-y)

Oien, K.A. and Dennis, J.L. (2012) Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Annals of Oncology, 23(Sup 10), x271-x277. (doi:10.1093/annonc/mds357)

Jamieson, N. B., Morran, D. C., Morton, J. P. , Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J. , Evans, T. R. J. , McKay, C. J. and Oien, K. A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18(2), pp. 534-545. (doi:10.1158/1078-0432.CCR-11-0679)

Greco, F.A., Oien, K., Erlander, M., Osborne, R., Varadhachary, G., Bridgewater, J., Cohen, D. and Wasan, H. (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Annals of Oncology, 23(2), pp. 298-304. (doi:10.1093/annonc/mdr306)

2011

Steele, C.W., Oien, K.A., McKay, C.J. and Jamieson, N.B. (2011) Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas, 40(8), pp. 1165-1171. (doi:10.1097/MPA.0b013e3182218ffb)

Kennedy, A.l. et al. (2011) Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. Molecular Cell, 42(1), pp. 36-49. (doi:10.1016/j.molcel.2011.02.020)

Roxburgh, C., McDonald, A., Salmond, J., Oien, K., Anderson, J., McKee, R., Horgan, P. and McMillan, D. (2011) Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. International Journal of Colorectal Disease, 26(4), pp. 483-492. (doi:10.1007/s00384-010-1120-5)

Jamieson, N.B., Foulis, A.K., Oien, K.A., Dickson, E.J., Imrie, C.W., Carter, R. and McKay, C.J. (2011) Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 15(3), pp. 512-524. (doi:10.1007/s11605-010-1395-4)

Jamieson, N.B., Carter, C.R., McKay, C.J. and Oien, K.O. (2011) Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 17(10), pp. 3316-3331. (doi:10.1158/1078-0432.CCR-10-3284)

2010

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(1), pp. 246-251. (doi:10.1073/pnas.0908428107)

Hannigan, A. et al. (2010) Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, 120(8), pp. 2842-2857. (doi:10.1172/JCI36125)

Jamieson, N. B., Foulis, A. K., Oien, K. A., Going, J. J., Glen, P., Dickson, E. J., Imrie, C. W., McKay, C. J. and Carter, R. (2010) Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 251(6), pp. 1003-1010. (doi:10.1097/SLA.0b013e3181d77369)

Lafferty-Whyte, K. et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 11(1), p. 532. (doi:10.1186/1471-2164-11-532)

Morris, J.M., Oien, K.A., McMahon, M., Forrest, E.H., Morris, J.M., Stanley, A.J. and Campbell, S. (2010) Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. European Journal of Gastroenterology and Hepatology, 22(8), pp. 1001-1005. (doi:10.1097/MEG.0b013e3283360021)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139(2), 586-597.e6. (doi:10.1053/j.gastro.2010.04.055)

Morton, J. et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139(1), pp. 292-303. (doi:10.1053/j.gastro.2010.03.034)

2009

Roxburgh, C.S., Salmond, J.M., Horgan, P.G. , Oien, K.A. and McMillan, D.C. (2009) Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. European Journal of Cancer, 45(12), pp. 2138-2145. (doi:10.1016/j.ejca.2009.04.011)

Roxburgh, C.S.D., Salmond, J.M., Horgan, P.G. , Oien, K.A. and McMillan, D.C. (2009) Comparison of the prognostic value of inflammation based pathological and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Annals of Surgery, 249(5), pp. 788-793. (doi:10.1097/SLA.0b013e3181a3e738)

Lafferty-Whyte, K., Cairney, C.J., Jamieson, N., Oien, K.A. and Keith, W.N. (2009) Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1792(4), pp. 341-352. (doi:10.1016/j.bbadis.2009.02.003)

Oien, K. (2009) Pathologic Evaluation of Unknown Primary Cancer. Seminars in Oncology, 36(1), pp. 8-37. (doi:10.1053/j.seminoncol.2008.10.009)

Roxburgh, C.S.D., Salmond, J.M., Horgan, P.G. , Oien, K.A. and McMillan, D.C. (2009) The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. Journal of Gastrointestinal Surgery, 13(11), pp. 2011-2019. (doi:10.1007/s11605-009-1034-0)

2008

Oien, K. and Evans, T. (2008) Raising the profile of cancer of unknown primary. Journal of Clinical Oncology, 26(27), pp. 4373-4375. (doi:10.1200/JCO.2008.17.6156)

de Graeff, P. et al. (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. British Journal of Cancer, 99(2), pp. 341-349. (doi:10.1038/sj.bjc.6604471)

2007

Nijhuis, E., Nijman, H., Oien, K., Bell, A., Ten Hoor, K., Reesink-Peters, N., Boezen, H., Hollema, H. and van der Zee, A. (2007) Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. Journal of Clinical Pathology, 60(7), pp. 824-830. (doi:10.1136/jcp.2005.036038)

Motazakker, M., Preikschat, P., Elliott, J., Smith, C., Mills, P., Oien, K., Spence, E., Elliott, R. and McCruden, E. (2007) Translation efficiencies of the 5 '-untranslated region of genotypes 1a and 3a in hepatitis C infected patients. Journal of Medical Virology, 79(3), pp. 259-269. (doi:10.1002/jmv.20794)

Oien, K.A., Dennis, J.L. and Evans, T.R.J. (2007) Metastatic adenocarcinoma of unknown origin. In: Kirkham, N. and Shepherd, N.A. (eds.) Progress in Pathology. Cambridge University Press: Cambridge, UK, pp. 135-162. ISBN 9780521694599

Oien, K.A., Stewart, I. and Evans, T.R.J. (2007) Unknown primary. In: Alison, M. (ed.) Cancer Handbook. John Wiley: Chichester, UK. ISBN 9780470018521

2006

Derakhshan, M., El Omar, E., Oien, K., Gillen, D., Fyfe, V., Crabtree, J. and McColl, K. (2006) Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. Journal of Clinical Pathology, 59(12), pp. 1293-1299. (doi:10.1136/jcp.2005.036111)

Otto, W. et al. (2006) Identification of blottin: A novel gastric trefoil factor family-2 binding protein. Proteomics, 6(15), pp. 4235-4245. (doi:10.1002/pmic.200500911)

de Graeff, P. et al. (2006) Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. British Journal of Cancer, 95(5), pp. 627-633. (doi:10.1038/sj.bjc.6603300)

Sansom, O. et al. (2006) Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proceedings of the National Academy of Sciences of the United States of America, 103(38), pp. 14122-14127. (doi:10.1073/pnas.0604130103)

2005

Forrest, E., Thorburn, D., Spence, E., Oien, K., Inglis, G., Smith, C., McCruden, E., Fox, R. and Mills, P. (2005) Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 12(5), pp. 519-524. (doi:10.1111/j.1365-2893.2005.00630.x)

Strathdee, G., Vass, J., Oien, K., Siddiqui, N., Curto-Garcia, J. and Brown, R. (2005) Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecologic Oncology, 97(3), pp. 898-903. (doi:10.1016/j.ygyno.2005.03.023)

Gaya, D., Oien, K., Stanley, A. and Morris, A. (2005) Bleeding gastric varices and antiphospholipid syndrome. Nature Clinical Practice Gastroenterology and Hepatology, 2(3), pp. 156-159. (doi:10.1038/ncpgasthep0110)

Dennis, J. and Oien, K. (2005) Hunting the primary: novel strategies for defining the origin of tumours. Journal of Pathology, 205(2), pp. 236-247. (doi:10.1002/path.1702)

Dennis, J. et al. (2005) Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm. Clinical Cancer Research, 11(10), pp. 3766-3772.

Hagan, S., Al-Mulla, F., Mallon, E., Oien, K., Ferrier, R., Gusterson, B., Garcia, J. and Kolch, W. (2005) Reduction of raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clinical Cancer Research, 11(20), pp. 7392-7397. (doi:10.1158/1078-0432.CCR-05-0283)

Westra, J. et al. (2005) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Annals of Oncology, 16(10), pp. 1646-1653. (doi:10.1093/annonc/mdi316)

2004

Gaya, D., Oien, K. and Fox, J. (2004) Duodenal vasculitis. Gastrointestinal Endoscopy, 60(4), pp. 602-603. (doi:10.1016/S0016-5107(04)01876-0)

Gaya, D., McLay, A., Oien, K., Spooner, R. and Reilly, T. (2004) A tale of two sisters. Journal of Clinical Pathology, 57(4), pp. 439-441. (doi:10.1136/jcp.2003.012013)

Oien, K.A., McGregor, F., Butler, S., Ferrier, R.K., Downie, I., Bryce, S., Burns, S. and Keith, W.N. (2004) Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation. Journal of Pathology, 203(3), pp. 789-797. (doi:10.1002/path.1583)

2003

Gaya, D., Thorburn, D., Oien, K., Morris, A. and Stanley, A. (2003) Hepatic granulomas: a 10 year single centre experience. Journal of Clinical Pathology, 56(11), pp. 850-853. (doi:10.1136/jcp.56.11.850)

Dennis, J., Westra, J., Bell, A., Montgomery, K. and Oien, K. (2003) The type and quality of paraffin wax is important when constructing tissue microarrays. Journal of Clinical Pathology-Molecular Pathology, 56(5), p. 306. (doi:10.1136/mp.56.5.306)

Cooper, L., Palmer, M. and Oien, K. (2003) Cirrhosis with steatohepatitis following longterm stilboestrol treatment. Journal of Clinical Pathology, 56(8), p. 639. (doi:10.1136/jcp.56.8.639)

Oien, K.A. (2003) Serial analysis of gene expression (SAGETM). In: Bartlett, J.M.S. and Stirling, D. (eds.) PCR Protocols. Series: Methods in molecular biology (226). Humana Press: Totowa, NJ, USA. ISBN 9780896036420

Oien, K.A., Vass, J.K., Downie, I., Fullarton, G. and Keith, W.N. (2003) Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene, 22(27), pp. 4287-4300. (doi:10.1038/sj.onc.1206615)

2002

Evans, C., Oien, K., MacSween, R. and Mills, P. (2002) Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? Journal of Clinical Pathology, 55(9), pp. 689-692. (doi:10.1136/jcp.55.9.689)

Forrest, E., Oien, K., Dickson, S., Galloway, D. and Mills, P. (2002) Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha. Liver, 22(4), pp. 317-320.

Thorburn, D., Curry, G., Spooner, R., Spence, E., Oien, K., Halls, D., Fox, R., McCruden, E., MacSween, R. and Mills, P. (2002) The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut, 50(2), pp. 248-252. (doi:10.1136/gut.50.2.248)

Dennis, J.L., Vass, J.K., Wit, E.C., Keith, W.N. and Oien, K.A. (2002) Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Research, 62(21), pp. 5999-6005.

2001

Nandini, C., Lindop, G., Gillen, D., Hendry, A. and Oien, K. (2001) Iron-induced oesophageal injury and pigmentation. Histopathology, 39(6), pp. 643-645.

Seow, C.S., Teo, N.B., Wilson, C.R. and Oien, K.A. (2001) Attitudes and training of research fellows in surgery: national questionnaire survey. British Medical Journal, 323(7315), pp. 725-726. (doi:10.1136/bmj.323.7315.725)

2000

O'Donohue, J., Oien, K., Donaldson, J., Underhill, J., Clare, M., MacSween, R.N.M. and Mills, P.R. (2000) Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut, 47(5), pp. 717-720. (doi:10.1136/gut.47.5.717) (PMID:11034591) (PMCID:PMC1728095)

Moffat, D.F., Oien, K.A., Dickson, J., Habeshaw, T. and McLellan, D.R. (2000) Hepatocellular carcinoma after long-term tamoxifen therapy. Annals of Oncology, 11(9), pp. 1195-6. (PMID:11061618)

El–Omar, E. M., Oien, K., Murray, L. S., El–Nujumi, A., Wirz, A., Gillen, D., Williams, C., Fullarton, G. and McColl, K. E.L. (2000) Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology, 118(1), pp. 22-30. (doi:10.1016/S0016-5085(00)70410-0) (PMID:10611150)

1999

Smith, G.A., Oien, K.A. and O'Dwyer, P.J. (1999) Frequency of early colorectal cancer in patients undergoing colonoscopy. British Journal of Surgery, 86(10), pp. 1328-1331. (doi:10.1046/j.1365-2168.1999.01226.x) (PMID:10540143)

Dorrance, H. R., Oien, K. and O'Dwyer, P. J. (1999) Effects of laparoscopy on intraperitoneal tumor growth and distant metastases in an animal model. Surgery, 126(1), pp. 35-40. (doi:10.1067/msy.1999.99056) (PMID:10418590)

Oien, K. A., Moffat, D., Curry, G. W., Dickson, J., Habeshaw, T., Mills, P. R. and MacSween, R. N. (1999) Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet, 353(9146), pp. 36-37. (doi:10.1016/S0140-6736(05)74872-8)

1998

Oien, K., Akyol, M. and Lindop, G. (1998) Neuroendocrine cell hyperplasia in colonic tissue used for long term augmentation cystoplasty. Journal of Clinical Pathology, 51(3), pp. 258-261. (PMID:9659277) (PMCID:PMC500656)

El-Nujumi, A., Williams, C., Ardill, J.E., Oien, K. and McColl, K.E.L. (1998) Eradicating helicobacter pylori reduces hypergastrinaemia during long term omeprazole treatment. Gut, 42(2), pp. 159-165. (doi:10.1136/gut.42.2.159) (PMID:9536937) (PMCID:PMC1727003)

1997

El-Omar, E.M., Oien, K., El-Nujumi, A., Gillen, D., Wirz, A., Dahill, S., Williams, C., Ardill, J.E. and McColl, K.E. (1997) Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology, 113(1), pp. 15-24. (doi:10.1016/S0016-5085(97)70075-1) (PMID:9207257)

Stephen, M.R., Oien, K., Ferrier, R.K. and Burnett, R.A. (1997) Effusion cytology of hepatocellular carcinoma with in situ hybridisation for human albumin. Journal of Clinical Pathology, 50(5), pp. 442-4. (PMID:9215133) (PMCID:PMC499952)

1995

Oien, K.A., Black, A., Hunter, J.A. and Madhok, R. (1995) Pneumocystis carinii pneumonia in a patient with rheumatoid arthritis, not on immunosuppressive therapy and in the absence of human immunodeficiency virus infection. Rheumatology, 34(7), pp. 677-679. (doi:10.1093/rheumatology/34.7.677) (PMID:7670789)

This list was generated on Sun Dec 16 17:08:21 2018 GMT.
Number of items: 86.

Articles

Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3(6), e000408. (doi:10.1136/esmoopen-2018-000408) (PMID:30233821) (PMCID:PMC6135448)

Williams, B. J., Lee, J., Oien, K. A. and Treanor, D. (2018) Digital pathology access and usage in the UK: results from a national survey on behalf of the National Cancer Research Institute's CM-Path initiative. Journal of Clinical Pathology, 71(5), pp. 463-466. (doi:10.1136/jclinpath-2017-204808) (PMID:29317516) (PMCID:PMC5916098)

Moore, D. A., Young, C. A., Morris, H. T., Oien, K. A., Lee, J. L., Jones, J. L. and Salto-Tellez, M. (2018) Time for change: a new training programme for morpho-molecular pathologists? Journal of Clinical Pathology, 71(4), pp. 285-290. (doi:10.1136/jclinpath-2017-204821) (PMID:29113995) (PMCID:PMC5868526)

Ali, A., Ali, Z., Yousafzai, Y. M. and Oien, K. A. (2018) Cancer biomarker development from basic science to clinical practice. Journal of Postgraduate Medical Institute, 32(1), pp. 3-8.

Jones, J. L., Oien, K. A., Lee, J. L. and Salto-Tellez, M. (2017) Morphomolecular pathology: setting the framework for a new generation of pathologists. British Journal of Cancer, 117(11), pp. 1581-1582. (doi:10.1038/bjc.2017.340) (PMID:29123262) (PMCID:PMC5729440)

Wong, N. A.C.S., Adamczyk, L. A., Evans, S., Cullen, J., Oniscu, A. and Oien, K. A. (2017) A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma. Histopathology, 71(1), pp. 34-41. (doi:10.1111/his.13194) (PMID:28226180)

Jones, W., Allardice, G., Scott, I., Oien, K., Brewster, D. and Morrison, D. S. (2017) Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer, 17, 85. (doi:10.1186/s12885-017-3083-1) (PMID:28143449) (PMCID:PMC5282907)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi:10.1053/j.gastro.2016.09.060) (PMID:27856273)

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi:10.1097/PAI.0000000000000357) (PMID:27093449)

Fizazi, K., Greco, F. A., Pavlidis, N., Daugaard, G., Oien, K. and Pentheroudakis, G. (2015) Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26(Sup 5), v133-v138. (doi:10.1093/annonc/mdv305) (PMID:26314775)

McGlynn, L. M., McCluney, S., Jamieson, N. B., Thomson, J., MacDonald, A. I., Oien, K., Dickson, E. J., Carter, C. R., McKay, C. J. and Shiels, P. G. (2015) SIRT3 & SIRT7: potential novel biomarkers for determining outcome in pancreatic cancer patients. PLoS ONE, 10(6), e0131344. (doi:10.1371/journal.pone.0131344) (PMID:26121130) (PMCID:PMC4487247)

Venkatpurwar, V.P., Rhodes, S. , Oien, K.A., Elliott, M.A., Tekwe, C.D., Jorgensen, H.G. and Ravi Kumar, M.N.V. (2015) Drug- not carrier-dependent haematological and biochemical changes in a repeated dose study of cyclosporine encapsulated polyester nano- and micro-particles: size does not matter. Toxicology, 330, pp. 9-18. (doi:10.1016/j.tox.2015.01.017) (PMID:25637670)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Moyes, L. H., Oien, K. A., Foulis, A. K., Fullarton, G. M. and Going, J. J. (2015) Prevalent low-grade dysplasia: the strongest predictor of malignant progression in Barrett's columnar-lined oesophagus. Gut, 65(2), pp. 360-361. (doi:10.1136/gutjnl-2015-309978) (PMID:26085438) (PMCID:PMC4752652)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Mabvuure, N. T., Maclean, L., Oien, K. and Gaya, D. (2014) Cytomegalovirus pouchitis in a patient with Crohn's disease. BMJ Case Reports, 2014(jul17), bcr2014205374-bcr2014205374. (doi:10.1136/bcr-2014-205374) (PMID:25035450)

Brewster, D. H., Lang, J., Bhatti, L. A., Thomson, C. S. and Oien, K. A. (2014) Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010. Cancer Epidemiology, 38(3), pp. 227-234. (doi:10.1016/j.canep.2014.03.010) (PMID:24726751)

Ali, A. et al. (2014) Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 14, p. 35. (doi:10.1186/1472-6890-14-35)

Denley, S.M., Jamieson, N.B., McCall, P., Oien, K.C.S., Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi:10.1007/s11605-013-2168-7)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868) (PMID:23439753)

Radulescu, S. et al. (2013) Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene, 32(16), pp. 2048-2057. (doi:10.1038/onc.2012.224)

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi:10.1083/jcb.201203025)

Jamieson, N.B., Mohamed, M., Oien, K.A., Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, C.R., McKay, C.J. and McMillan, D.C. (2012) The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 19(11), pp. 3581-3590. (doi:10.1245/s10434-012-2370-y)

Oien, K.A. and Dennis, J.L. (2012) Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Annals of Oncology, 23(Sup 10), x271-x277. (doi:10.1093/annonc/mds357)

Jamieson, N. B., Morran, D. C., Morton, J. P. , Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J. , Evans, T. R. J. , McKay, C. J. and Oien, K. A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18(2), pp. 534-545. (doi:10.1158/1078-0432.CCR-11-0679)

Greco, F.A., Oien, K., Erlander, M., Osborne, R., Varadhachary, G., Bridgewater, J., Cohen, D. and Wasan, H. (2012) Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Annals of Oncology, 23(2), pp. 298-304. (doi:10.1093/annonc/mdr306)

Steele, C.W., Oien, K.A., McKay, C.J. and Jamieson, N.B. (2011) Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas, 40(8), pp. 1165-1171. (doi:10.1097/MPA.0b013e3182218ffb)

Kennedy, A.l. et al. (2011) Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. Molecular Cell, 42(1), pp. 36-49. (doi:10.1016/j.molcel.2011.02.020)

Roxburgh, C., McDonald, A., Salmond, J., Oien, K., Anderson, J., McKee, R., Horgan, P. and McMillan, D. (2011) Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. International Journal of Colorectal Disease, 26(4), pp. 483-492. (doi:10.1007/s00384-010-1120-5)

Jamieson, N.B., Foulis, A.K., Oien, K.A., Dickson, E.J., Imrie, C.W., Carter, R. and McKay, C.J. (2011) Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 15(3), pp. 512-524. (doi:10.1007/s11605-010-1395-4)

Jamieson, N.B., Carter, C.R., McKay, C.J. and Oien, K.O. (2011) Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 17(10), pp. 3316-3331. (doi:10.1158/1078-0432.CCR-10-3284)

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(1), pp. 246-251. (doi:10.1073/pnas.0908428107)

Hannigan, A. et al. (2010) Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. Journal of Clinical Investigation, 120(8), pp. 2842-2857. (doi:10.1172/JCI36125)

Jamieson, N. B., Foulis, A. K., Oien, K. A., Going, J. J., Glen, P., Dickson, E. J., Imrie, C. W., McKay, C. J. and Carter, R. (2010) Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 251(6), pp. 1003-1010. (doi:10.1097/SLA.0b013e3181d77369)

Lafferty-Whyte, K. et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 11(1), p. 532. (doi:10.1186/1471-2164-11-532)

Morris, J.M., Oien, K.A., McMahon, M., Forrest, E.H., Morris, J.M., Stanley, A.J. and Campbell, S. (2010) Nodular regenerative hyperplasia of the liver: survival and associated features in a UK case series. European Journal of Gastroenterology and Hepatology, 22(8), pp. 1001-1005. (doi:10.1097/MEG.0b013e3283360021)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139(2), 586-597.e6. (doi:10.1053/j.gastro.2010.04.055)

Morton, J. et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139(1), pp. 292-303. (doi:10.1053/j.gastro.2010.03.034)

Roxburgh, C.S., Salmond, J.M., Horgan, P.G. , Oien, K.A. and McMillan, D.C. (2009) Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. European Journal of Cancer, 45(12), pp. 2138-2145. (doi:10.1016/j.ejca.2009.04.011)

Roxburgh, C.S.D., Salmond, J.M., Horgan, P.G. , Oien, K.A. and McMillan, D.C. (2009) Comparison of the prognostic value of inflammation based pathological and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Annals of Surgery, 249(5), pp. 788-793. (doi:10.1097/SLA.0b013e3181a3e738)

Lafferty-Whyte, K., Cairney, C.J., Jamieson, N., Oien, K.A. and Keith, W.N. (2009) Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1792(4), pp. 341-352. (doi:10.1016/j.bbadis.2009.02.003)

Oien, K. (2009) Pathologic Evaluation of Unknown Primary Cancer. Seminars in Oncology, 36(1), pp. 8-37. (doi:10.1053/j.seminoncol.2008.10.009)

Roxburgh, C.S.D., Salmond, J.M., Horgan, P.G. , Oien, K.A. and McMillan, D.C. (2009) The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. Journal of Gastrointestinal Surgery, 13(11), pp. 2011-2019. (doi:10.1007/s11605-009-1034-0)

Oien, K. and Evans, T. (2008) Raising the profile of cancer of unknown primary. Journal of Clinical Oncology, 26(27), pp. 4373-4375. (doi:10.1200/JCO.2008.17.6156)

de Graeff, P. et al. (2008) The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. British Journal of Cancer, 99(2), pp. 341-349. (doi:10.1038/sj.bjc.6604471)

Nijhuis, E., Nijman, H., Oien, K., Bell, A., Ten Hoor, K., Reesink-Peters, N., Boezen, H., Hollema, H. and van der Zee, A. (2007) Loss of MSH2 protein expression is a risk factor in early stage cervical cancer. Journal of Clinical Pathology, 60(7), pp. 824-830. (doi:10.1136/jcp.2005.036038)

Motazakker, M., Preikschat, P., Elliott, J., Smith, C., Mills, P., Oien, K., Spence, E., Elliott, R. and McCruden, E. (2007) Translation efficiencies of the 5 '-untranslated region of genotypes 1a and 3a in hepatitis C infected patients. Journal of Medical Virology, 79(3), pp. 259-269. (doi:10.1002/jmv.20794)

Derakhshan, M., El Omar, E., Oien, K., Gillen, D., Fyfe, V., Crabtree, J. and McColl, K. (2006) Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. Journal of Clinical Pathology, 59(12), pp. 1293-1299. (doi:10.1136/jcp.2005.036111)

Otto, W. et al. (2006) Identification of blottin: A novel gastric trefoil factor family-2 binding protein. Proteomics, 6(15), pp. 4235-4245. (doi:10.1002/pmic.200500911)

de Graeff, P. et al. (2006) Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. British Journal of Cancer, 95(5), pp. 627-633. (doi:10.1038/sj.bjc.6603300)

Sansom, O. et al. (2006) Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proceedings of the National Academy of Sciences of the United States of America, 103(38), pp. 14122-14127. (doi:10.1073/pnas.0604130103)

Forrest, E., Thorburn, D., Spence, E., Oien, K., Inglis, G., Smith, C., McCruden, E., Fox, R. and Mills, P. (2005) Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 12(5), pp. 519-524. (doi:10.1111/j.1365-2893.2005.00630.x)

Strathdee, G., Vass, J., Oien, K., Siddiqui, N., Curto-Garcia, J. and Brown, R. (2005) Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecologic Oncology, 97(3), pp. 898-903. (doi:10.1016/j.ygyno.2005.03.023)

Gaya, D., Oien, K., Stanley, A. and Morris, A. (2005) Bleeding gastric varices and antiphospholipid syndrome. Nature Clinical Practice Gastroenterology and Hepatology, 2(3), pp. 156-159. (doi:10.1038/ncpgasthep0110)

Dennis, J. and Oien, K. (2005) Hunting the primary: novel strategies for defining the origin of tumours. Journal of Pathology, 205(2), pp. 236-247. (doi:10.1002/path.1702)

Dennis, J. et al. (2005) Markers of adenocarcinoma characteristic of the site of origin: Development of a diagnostic algorithm. Clinical Cancer Research, 11(10), pp. 3766-3772.

Hagan, S., Al-Mulla, F., Mallon, E., Oien, K., Ferrier, R., Gusterson, B., Garcia, J. and Kolch, W. (2005) Reduction of raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clinical Cancer Research, 11(20), pp. 7392-7397. (doi:10.1158/1078-0432.CCR-05-0283)

Westra, J. et al. (2005) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Annals of Oncology, 16(10), pp. 1646-1653. (doi:10.1093/annonc/mdi316)

Gaya, D., Oien, K. and Fox, J. (2004) Duodenal vasculitis. Gastrointestinal Endoscopy, 60(4), pp. 602-603. (doi:10.1016/S0016-5107(04)01876-0)

Gaya, D., McLay, A., Oien, K., Spooner, R. and Reilly, T. (2004) A tale of two sisters. Journal of Clinical Pathology, 57(4), pp. 439-441. (doi:10.1136/jcp.2003.012013)

Oien, K.A., McGregor, F., Butler, S., Ferrier, R.K., Downie, I., Bryce, S., Burns, S. and Keith, W.N. (2004) Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation. Journal of Pathology, 203(3), pp. 789-797. (doi:10.1002/path.1583)

Gaya, D., Thorburn, D., Oien, K., Morris, A. and Stanley, A. (2003) Hepatic granulomas: a 10 year single centre experience. Journal of Clinical Pathology, 56(11), pp. 850-853. (doi:10.1136/jcp.56.11.850)

Dennis, J., Westra, J., Bell, A., Montgomery, K. and Oien, K. (2003) The type and quality of paraffin wax is important when constructing tissue microarrays. Journal of Clinical Pathology-Molecular Pathology, 56(5), p. 306. (doi:10.1136/mp.56.5.306)

Cooper, L., Palmer, M. and Oien, K. (2003) Cirrhosis with steatohepatitis following longterm stilboestrol treatment. Journal of Clinical Pathology, 56(8), p. 639. (doi:10.1136/jcp.56.8.639)

Oien, K.A., Vass, J.K., Downie, I., Fullarton, G. and Keith, W.N. (2003) Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. Oncogene, 22(27), pp. 4287-4300. (doi:10.1038/sj.onc.1206615)

Evans, C., Oien, K., MacSween, R. and Mills, P. (2002) Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? Journal of Clinical Pathology, 55(9), pp. 689-692. (doi:10.1136/jcp.55.9.689)

Forrest, E., Oien, K., Dickson, S., Galloway, D. and Mills, P. (2002) Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha. Liver, 22(4), pp. 317-320.

Thorburn, D., Curry, G., Spooner, R., Spence, E., Oien, K., Halls, D., Fox, R., McCruden, E., MacSween, R. and Mills, P. (2002) The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut, 50(2), pp. 248-252. (doi:10.1136/gut.50.2.248)

Dennis, J.L., Vass, J.K., Wit, E.C., Keith, W.N. and Oien, K.A. (2002) Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Research, 62(21), pp. 5999-6005.

Nandini, C., Lindop, G., Gillen, D., Hendry, A. and Oien, K. (2001) Iron-induced oesophageal injury and pigmentation. Histopathology, 39(6), pp. 643-645.

Seow, C.S., Teo, N.B., Wilson, C.R. and Oien, K.A. (2001) Attitudes and training of research fellows in surgery: national questionnaire survey. British Medical Journal, 323(7315), pp. 725-726. (doi:10.1136/bmj.323.7315.725)

O'Donohue, J., Oien, K., Donaldson, J., Underhill, J., Clare, M., MacSween, R.N.M. and Mills, P.R. (2000) Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut, 47(5), pp. 717-720. (doi:10.1136/gut.47.5.717) (PMID:11034591) (PMCID:PMC1728095)

Moffat, D.F., Oien, K.A., Dickson, J., Habeshaw, T. and McLellan, D.R. (2000) Hepatocellular carcinoma after long-term tamoxifen therapy. Annals of Oncology, 11(9), pp. 1195-6. (PMID:11061618)

El–Omar, E. M., Oien, K., Murray, L. S., El–Nujumi, A., Wirz, A., Gillen, D., Williams, C., Fullarton, G. and McColl, K. E.L. (2000) Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology, 118(1), pp. 22-30. (doi:10.1016/S0016-5085(00)70410-0) (PMID:10611150)

Smith, G.A., Oien, K.A. and O'Dwyer, P.J. (1999) Frequency of early colorectal cancer in patients undergoing colonoscopy. British Journal of Surgery, 86(10), pp. 1328-1331. (doi:10.1046/j.1365-2168.1999.01226.x) (PMID:10540143)

Dorrance, H. R., Oien, K. and O'Dwyer, P. J. (1999) Effects of laparoscopy on intraperitoneal tumor growth and distant metastases in an animal model. Surgery, 126(1), pp. 35-40. (doi:10.1067/msy.1999.99056) (PMID:10418590)

Oien, K. A., Moffat, D., Curry, G. W., Dickson, J., Habeshaw, T., Mills, P. R. and MacSween, R. N. (1999) Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet, 353(9146), pp. 36-37. (doi:10.1016/S0140-6736(05)74872-8)

Oien, K., Akyol, M. and Lindop, G. (1998) Neuroendocrine cell hyperplasia in colonic tissue used for long term augmentation cystoplasty. Journal of Clinical Pathology, 51(3), pp. 258-261. (PMID:9659277) (PMCID:PMC500656)

El-Nujumi, A., Williams, C., Ardill, J.E., Oien, K. and McColl, K.E.L. (1998) Eradicating helicobacter pylori reduces hypergastrinaemia during long term omeprazole treatment. Gut, 42(2), pp. 159-165. (doi:10.1136/gut.42.2.159) (PMID:9536937) (PMCID:PMC1727003)

El-Omar, E.M., Oien, K., El-Nujumi, A., Gillen, D., Wirz, A., Dahill, S., Williams, C., Ardill, J.E. and McColl, K.E. (1997) Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology, 113(1), pp. 15-24. (doi:10.1016/S0016-5085(97)70075-1) (PMID:9207257)

Stephen, M.R., Oien, K., Ferrier, R.K. and Burnett, R.A. (1997) Effusion cytology of hepatocellular carcinoma with in situ hybridisation for human albumin. Journal of Clinical Pathology, 50(5), pp. 442-4. (PMID:9215133) (PMCID:PMC499952)

Oien, K.A., Black, A., Hunter, J.A. and Madhok, R. (1995) Pneumocystis carinii pneumonia in a patient with rheumatoid arthritis, not on immunosuppressive therapy and in the absence of human immunodeficiency virus infection. Rheumatology, 34(7), pp. 677-679. (doi:10.1093/rheumatology/34.7.677) (PMID:7670789)

Book Sections

Oien, K.A., Dennis, J.L. and Evans, T.R.J. (2007) Metastatic adenocarcinoma of unknown origin. In: Kirkham, N. and Shepherd, N.A. (eds.) Progress in Pathology. Cambridge University Press: Cambridge, UK, pp. 135-162. ISBN 9780521694599

Oien, K.A., Stewart, I. and Evans, T.R.J. (2007) Unknown primary. In: Alison, M. (ed.) Cancer Handbook. John Wiley: Chichester, UK. ISBN 9780470018521

Oien, K.A. (2003) Serial analysis of gene expression (SAGETM). In: Bartlett, J.M.S. and Stirling, D. (eds.) PCR Protocols. Series: Methods in molecular biology (226). Humana Press: Totowa, NJ, USA. ISBN 9780896036420

This list was generated on Sun Dec 16 17:08:21 2018 GMT.